Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
MCM4 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P33991 |
|---|---|
| Clone Names | 100525163 |
| Gene ID | 4173 |
|---|---|
| Other Names | DNA replication licensing factor MCM4, CDC21 homolog, P1-CDC21, MCM4, CDC21 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | MCM4 (HGNC:6947) |
|---|---|
| Synonyms | CDC21 |
| Function | Acts as a component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:16899510, PubMed:25661590, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425, PubMed:16899510, PubMed:25661590, PubMed:9305914). |
| Cellular Location | Nucleus. Chromosome. Note=Associated with chromatin before the formation of nuclei and detaches from it as DNA replication progresses. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is one of the highlyconserved mini-chromosome maintenance proteins (MCM) that areessential for the initiation of eukaryotic genome replication. Thehexameric protein complex formed by MCM proteins is a key componentof the pre-replication complex (pre_RC) and may be involved in theformation of replication forks and in the recruitment of other DNAreplication related proteins. The MCM complex consisting of thisprotein and MCM2, 6 and 7 proteins possesses DNA helicase activity,and may act as a DNA unwinding enzyme. The phosphorylation of thisprotein by CDC2 kinase reduces the DNA helicase activity andchromatin binding of the MCM complex. This gene is mapped to aregion on the chromosome 8 head-to-head next to the PRKDC/DNA-PK, aDNA-activated protein kinase involved in the repair of DNAdouble-strand breaks. Alternatively spliced transcript variantsencoding the same protein have been reported.
References
Olson, J.E., et al. Breast Cancer Res. Treat. (2010) In press :Qian, Z., et al. PLoS Pathog. 6 (3), E1000814 (2010) :Ladstein, R.G., et al. BMC Cancer 10, 140 (2010) :Hosgood, H.D. III, et al. Occup Environ Med 66(12):848-853(2009)Enjuanes, A., et al. Cancer Res. 68(24):10178-10186(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
